Drug Type Monoclonal antibody |
Synonyms SGN17/19 |
Target- |
Mechanism ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Immunostimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | Preclinical | US | - | |
Melanoma | Preclinical | US | - |